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Not surprisingly, patients perceive a considerable reduction
of quality of life following impairment of their visual func-
tion. What perhaps few of us in the field of multiple sclerosis
realized is that patients rank loss of visual function second
only to loss of mobility [1]. Fittingly, this first of a series of
special issues comprises three reviews on the visual system
in multiple sclerosis and related disorders. From Canada, we
have F. Costello telling us that the saying “the patient does not
see anything, nor does the doctor” may become history with
the broader application of a rapidly evolving technology,
optical coherence tomography (OCT) in “Evaluating the use
of optical coherence tomography in optic neuritis.” The data
discussed in this review provides compelling evidence that
loss of retinal axons can be quantified with high accuracy.
Further extending this new technology, S. Noval et al.,
from Spain, conclude that OCT may “represent an objective
outcome measure” for treatment trials in “Optical coherence
tomography in multiple sclerosis and neuromyelitis optica: an
update” Indeed, several therapeutic trials in MS utilizing
OCT as a secondary outcome measure are in advanced
planning stages. Given the ease and speed of the examination,
OCT could become a valuable tool for the MS community.
Given the anatomical constraints of the human nervous
system, the technique is unlikely to pose a challenge to firmly
established magnetic resonance imaging (MRI) of the brain.
So those of us who spend hours sleeping as control subjects
in ever-increasing magnetic fields may continue collecting
colored ear plugs. In fact, the comprehensive review on MRI
of the visual pathways by C. Pfueller and F. Paul (Germany)
tells why these twomethods are complementary (in “Imaging
the visual pathway in neuromyelitis optica”). Nonetheless,
assessment of retinal nerve fibre layer thickness by OCT is
a readily accessible measure, unlike cerebral volume, and
one could imagine using this quantitative marker for routine
monitoring ofMS progression in the clinic in the near future.
The focus on the elusive cause of MS has shifted in this
special issue to possible mechanisms driving neurodegener-
ation, the major cause for sustained disability. From Italy
we have B. Tavazzi et al. presenting biomarker data which
suggests that oxidative damage hangs as a Damocles sword
over the impaired energy metabolism in axons damaged
in multiple sclerosis in “Serum metabolic profile in multiple
sclerosis patients.” One perennially popular candidate out of
Pandora’s box of oxidative damage is iron. In a beautiful
translational review M. Khalil et al. from Austria summarize
the evidence linking iron to neurodegeneration in MS (in
“Iron and neurodegeneration in multiple sclerosis”). Neurode-
generation in MS is a process which can be captured in time
by using specific biomarkers as illustrated by two compre-
hensive reviews by I. Dujmovic (Serbia) and M. M. Gresle
et al. (Australia) (“Cerebrospinal fluid and blood biomarkers of
neuroaxonal damage in multiple sclerosis” and “Neurofilament
proteins as body fluid biomarkers of neurodegeneration in
multiple sclerosis”). The lecture of these reviews brings to
the readers mind why it is so important to have biomarker
research standardized, reflected in a restated and updated
consensus paper on this issue by C. Teunissen et al. from The
Netherlands (titled “Consensus guidelines for CSF and blood
biobanking for CNS biomarker studies”). Would it not be
nice if we could measure neurodegeneration from a patient’s
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blood sample similar to what cardiologists can do with
troponin? M. J. Eikelenboom et al. also from The Nether-
lands remind us that our experience with cerebrospinal
fluid data (in “Cerebrospinal fluid and blood biomarkers of
neuroaxonal damage in multiple sclerosis” and “Neurofilament
proteins as body fluid biomarkers of neurodegeneration in
multiple sclerosis”) cannot readily be extrapolated to the
blood during the chronic phase of the disease in “Blood and
CSF biomarker dynamics in multiple sclerosis: implications for
data interpretation.” Unfortunately during the progressive
phase of multiple sclerosis, there is no general convincing
evidence for the eﬃcacy of disease-modifying drugs, and
experimental options such as repeated intrathecal steroids
are still under investigation as M. Abu-Mugheisib et al. from
Germany summarize (in “Repeated intrathecal triamcinolone
acetonide administration in progressive multiple sclerosis: a
review”). In this context the anecdotal observation by G.
T. Plant et al. from London that steroid treatment in the
hyperacute phase of optic neuritis prevents loss of vision is
remarkable (in “Hyperacute corticosteroid treatment of optic
neuritis at the onset of pain may prevent visual loss: a case
series”). The eight patients reported in this paper appear as
a David compared to the large Goliath-like dataset of the
Optic Neuritis Treatment Trial (ONTT) which demonstrated
that steroids did not change the outcome of visual function.
Nevertheless, small patient numbers might be suﬃcient if
the disease biology is clear-cut: James Lind only investigated
twelve sailors to find the cause and treatment for scurvy
[2]. The careful examination of patients with acute optic
neuritis by F. Costello et al. using OCT in “Exploring the
association between retinal nerve fiber layer thickness and
initial magnetic resonance imaging findings in patients with
acute optic neuritis” may just provide the outcome measure
needed for a future treatment trial in this direction.
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